Fig. 1: SARS-CoV-2 and MHV RNA were detected in different tissues.
From: Blood matters: the hematological signatures of Coronavirus infection
A (i) Schematic representation of sample acquisition from COVID-19 patients from Hospital Español (Administración de los Servicios de Salud del Estado, Uruguay). Nasopharyngeal swabs (n = 10) and lung, heart, and kidney samples from human autopsies (n = 8) were collected for viral load by RT-qPCR analysis. (ii) Viral load (log10(copy/mL) of nasopharyngeal swabs and samples from COVID-19 patients (P). (iii) Viral load (log10(copy/mL) of different organ samples (lung, heart, and kidney) obtained from patient autopsies. B (i) Experimental design of murine Coronavirus infection. BALB/cJ mice were infected with MHV-A59 by intranasal administration (4000 PFU) or by i.p. injection (6000 PFU). Five days post-infection (dpi), the liver, lung, brain, heart, kidney, spleen, and pancreas were dissected for RT-qPCR analyzes. (ii) Viral RNA abundance (−Ct) measured by RT-qPCR in liver, lung, brain, kidney, spleen, and pancreas samples from mice (n = 5) infected by intranasal administration. (iii) Viral RNA abundance (−Ct) measured by RT-qPCR (filled circles) and viral titer (log10(TCID50/g) (open circles) in liver, lung, brain, heart, kidney, spleen, and pancreas samples from mice (n = 6) infected by intraperitoneal administration. BDL below detection limit.
